A detailed history of Bnp Paribas transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Bnp Paribas holds 74,399 shares of GILD stock, worth $8.18 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
74,399
Previous 77,395 3.87%
Holding current value
$8.18 Million
Previous $6.49 Billion 99.89%
% of portfolio
0.3%
Previous 0.27%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$83.95 - $97.9 $251,514 - $293,308
-2,996 Reduced 3.87%
74,399 $6.87 Million
Q3 2024

Nov 13, 2024

SELL
$66.59 - $83.99 $267,691 - $337,639
-4,020 Reduced 4.94%
77,395 $6.49 Billion
Q2 2024

Aug 13, 2024

BUY
$63.15 - $72.88 $177,451 - $204,792
2,810 Added 3.57%
81,415 $5.58 Billion
Q1 2024

May 01, 2024

BUY
$71.58 - $87.29 $5.63 Million - $6.86 Million
78,605 New
78,605 $5.76 Billion

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $138B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Bnp Paribas Portfolio

Follow Bnp Paribas and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bnp Paribas, based on Form 13F filings with the SEC.

News

Stay updated on Bnp Paribas with notifications on news.